Equillium Inc Cash Flow Conversion Efficiency
Equillium Inc cash flow conversion efficiency. Based on the latest financial reports, Equillium Inc (EQ) has a cash flow conversion efficiency ratio of -0.073x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.11 Million) by net assets ($56.02 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Equillium Inc (2017–2025)
Cash flow conversion efficiency of Equillium Inc from 2017 to 2025. This chart illustrates how Equillium Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Equillium Inc stock quote for real-time trading data and today's change.
Equillium Inc Cash Flow Conversion Ratio Explained
Equillium Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Equillium Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Equillium Inc ranked by their cash flow conversion efficiency. Also see Equillium Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Dongzhu Landscape Co
SHG:603359
|
0.017x |
|
Agrify Corp
NASDAQ:AGFY
|
-0.459x |
|
Antony Waste Handling Cell Limited
NSE:AWHCL
|
0.036x |
|
Leofoo Development Co Ltd
TW:2705
|
0.006x |
|
Loop Telecommunication International Inc
TW:3025
|
0.069x |
|
OPPSTAR
KLSE:0275
|
0.029x |
|
Leadtrend Technology Corp
TW:3588
|
0.007x |
|
Country Group Holdings Public Company Limited
BK:CGH
|
0.024x |
Annual Cash Flow Conversion Efficiency for Equillium Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Equillium Inc from 2017 to 2025. Review how much free cash does Equillium Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $28.60 Million | $-22.75 Million | -0.795x | +20.31% |
| 2024-12-31 | $19.06 Million | $-19.03 Million | -0.998x | -3.44% |
| 2023-12-31 | $22.57 Million | $-21.78 Million | -0.965x | -252.96% |
| 2022-12-31 | $31.94 Million | $-8.73 Million | -0.273x | +43.32% |
| 2021-12-31 | $66.50 Million | $-32.08 Million | -0.482x | -36.84% |
| 2020-12-31 | $69.85 Million | $-24.62 Million | -0.353x | +35.72% |
| 2019-12-31 | $41.85 Million | $-22.95 Million | -0.548x | -373.14% |
| 2018-12-31 | $64.94 Million | $-7.53 Million | -0.116x | -139.42% |
| 2017-12-31 | $-2.25 Million | $-662.20K | 0.294x | -- |
About Equillium Inc
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 fo… Read more